Open Orphan wins vaccine contract extension and announces toxicology study completion
By Mark Sheridan
Published:
Disseminated on behalf of Open Orphan Plc
PAID ADVERTISEMENT
This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.
CHANGES IN SHARE TRADING AND PRICE
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.
NO OFFER TO SELL OR BUY SECURITIES
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.
INFORMATION
Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.
This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.
NO FINANCIAL ADVICE
The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR+ and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.
FORWARD LOOKING STATEMENTS
This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.
INDEMNIFICATION/RELEASE OF LIABILITY
By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.
TERMS OF USE AND DISCLAIMER
By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here https://www.valuethemarkets.com/disclaimer/. If you do not agree to the Terms of Use, please contact valuethemarkets.com to discontinue receiving future communications.
INTELLECTUAL PROPERTY
All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.
AUTHORS: VALUETHEMARKETS
valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.
ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.
In This Press Release
Loading...
Want to see what you should be buying? Check out our top picks.
usd
Open Orphan (LSE: ORPH) subsidiary Venn Life Sciences has extended a consulting contract with a global pharma firm to support two vaccine development programmes.
Venn’s Breda office in the Netherlands will handle chemistry, manufacturing and control duties for the client.
The unnamed buyer is one of the three largest pharmaceutical companies on the planet, Open Orphan said in an announcement on Tuesday.
The 12-month extension takes the Venn contract to December 2021.
“This contract renewal underpins our confidence in delivering against ambitious growth targets for 2021 and securing strong revenue visibility moving forward. As we remain on target to be operationally profitable in the final quarter of this year, we also expect to see a significant impact on next year’s earnings from this revenue growth.”
The update marks the third contract win for Venn announced in December 2020 alone. The company’s Paris branch won a contract to support a European pharma firm’s phase 2 clinical trial on Covid-19 to evaluate the safety of two drugs to treat patients with moderate and severe Covid in hospitals, while its Breda office signed an extended 12 month contract for a second Euro pharma player.
Work on both contracts starts immediately and runs to December 2021. Both would bring in “significant revenues” for Venn, Open Orphan said.
“Many pharmaceutical companies are substantially increasing their vaccine development spend and we expect that to continue in the months and years ahead as big pharma and governments rush to catch up on decades of extreme under-expenditure,”
– Cathal Friel, Executive Chairman for Open Orphan
“This reaffirms our belief that we are entering a period of exponential vaccine development globally and thus, exponential opportunity for the Open Orphan group, including Venn and hVIVO to support pharma companies in the space.”
Market analysts suggest that FY2021 revenues for the group are expected to hit £38 million, with net profits of around £7m.
Friel has said the group will end 2020 with more than £20 million in cash on its balance sheet.
Open Orphan took over Venn Life Sciences in a reverse takeover in June 2019, before merging with world-leading vaccine and antiviral testing firm hVIVO in January 2020.
Elsewhere, in a release on Wednesday, Open Orphan announced that drug development company PrEP Biopharm had successfully completed a 12-week toxicology study for its novel pan-viral prophylactic asset PrEP-001.
PrEP, which is 62.6% owned by ORPH, said the animal model study provides safety data needed to move PrEP-001 into longer duration dosing in clinical trials.
The company intends to move forward with a real-world, field trial to validate the efficacy of PrEP-001 against all circulating respiratory viruses, including COVID-19, influenza and the common cold.
PrEP-001 is neither a vaccine nor an antiviral but a synthetic RNA ‘viral mimic’ that stimulates the body’s pan-viral innate immune response locally in the upper respiratory tract.
It is administered via a once-daily nasal spray and leverages the innate immune system to create an all-encompassing antiviral environment.
This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.
